Completado

A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

immunohistochemistry staining method

+ biopsy

+ surgery

OtroProcedimiento
Quiénes están siendo reclutados

Adenocarcinoma+12

+ Neoplasias bronquiales

+ Carcinoma

A partir de 18 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio Diagnóstico

Fase 3
Intervencional
Inicio del estudio: julio de 1999
Ver detalles del protocolo

Resumen

Patrocinador PrincipalAlliance for Clinical Trials in Oncology
Última actualización: 16 de febrero de 2017
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de julio de 1999

Fecha en la que se inscribió al primer participante.

OBJECTIVES: Determine the relationship between three indicators of occult metastases (cytological examination of pleural lavage, immunohistochemistry (IHC) assay of lymph nodes, and IHC assay of rib bone marrow) and survival of patients with resectable non-small cell lung cancer. Determine the relationship between these indicators and conventional histology. Model survival considering the indicators and other patient attributes that are of prime prognostic significance. Determine the relationships between the indicators and the site of first recurrence in these patients. Determine the prevalence of the indicators in these patients. Determine the relationships between the indicators and disease free survival in these patients.

NCT00003901
Patrocinador PrincipalAlliance for Clinical Trials in Oncology
Última actualización: 16 de febrero de 2017
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 1310 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio Diagnóstico

Los estudios diagnósticos se centran en mejorar como se detecta o confirma una enfermedad. Prueban nuevas herramientas o técnicas que podrían ofrecer diagnósticos más rápidos o precisos.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

A partir de 18 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

AdenocarcinomaNeoplasias bronquialesCarcinomaCarcinoma broncogénicoEnfermedades del pulmónNeoplasiasNeoplasias por tipo histológicoNeoplasias por SitioNeoplasias glandulares y epitelialesEnfermedades del Tracto RespiratorioNeoplasias del tracto respiratorioNeoplasias torácicasAdenocarcinoma de pulmónCarcinoma de pulmón no microcíticoNeoplasmas Pulmonares

Criterios

Inclusion Criteria: Patient must be ≥ 18 years old. Patient must have ECOG/Zubrod status < 3. Patient must have clinically resectable, NSCLC (squamous cell, adenocarcinoma, or large cell) and be clinical Stage I, IIa, IIb or IIIa, according to the 1998 staging system of the American Joint Commission on Cancer for lung cancer. Patient must have N1 or N2 disease. NOTE: Patient must undergo mediastinoscopy if preoperative studies suggest N3 disease. Patient must have a pathologic diagnosis (pre-operative or intra-operative) of NSCLC prior to registration. Patient must be anticipated to have a thoracotomy with the intention of a curative resection for primary NSCLC. NOTE: The preoperative assessment of resectability should, at a minimum, include a CT scan of the chest and upper abdomen, including the adrenal glands, within 60 days prior to registration. Patient must be medically fit for surgery. Patient must be a candidate for complete resection of the carcinoma via pneumonectomy, bilobectomy, lobectomy, or anatomic segmentectomy with or without sleeve resection. Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures. Patient must be available for follow-up. If the patient is a survivor of a prior cancer, all of the following criteria must apply: Patient has undergone potentially curative therapy for all prior malignancies, No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone), Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies. Exclusion Criteria: Patient has evidence of pleural effusion by physical assessment, lateral chest x-ray, or by chest CT scan. Patient has had ipsilateral thoracotomy or thoracoscopy within the past 5 years. Patient has received prior chemotherapy or radiotherapy for this cancer. Patient is considered a poor surgical risk due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options. Patient for whom the surgeon plans to perform only a wedge resection for treatment.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

Un solo grupo de intervención está designado en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed. Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods. Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years.

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 58 ubicaciones

Providence Cancer Center

Mobile, United StatesAbrir Providence Cancer Center en Google Maps

Mobile Infirmary Medical Center

Mobile, United States

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, United States

Huntington Cancer Center at Huntington Hospital

Pasadena, United States
Completado58 Centros de Estudio